Last reviewed · How we verify
Flexeril Oral Product
Flexeril (cyclobenzaprine) is a centrally acting muscle relaxant that reduces muscle spasms by depressing activity in the brainstem.
Flexeril (cyclobenzaprine) is a centrally acting muscle relaxant that reduces muscle spasms by depressing activity in the brainstem. Used for Acute muscle spasm and pain associated with musculoskeletal conditions.
At a glance
| Generic name | Flexeril Oral Product |
|---|---|
| Also known as | Cyclobenziparin |
| Sponsor | University of California, Davis |
| Drug class | Centrally acting muscle relaxant |
| Modality | Small molecule |
| Therapeutic area | Neurology / Musculoskeletal |
| Phase | FDA-approved |
Mechanism of action
Cyclobenzaprine works primarily through central nervous system depression, likely by enhancing the effects of norepinephrine and other neurotransmitters at the brainstem level. It does not directly relax skeletal muscle or affect the neuromuscular junction, but rather reduces motor neuron activity and muscle tone through central mechanisms. The exact molecular target remains incompletely characterized, but it is structurally related to tricyclic antidepressants.
Approved indications
- Acute muscle spasm and pain associated with musculoskeletal conditions
Common side effects
- Drowsiness
- Dizziness
- Dry mouth
- Fatigue
- Headache
Key clinical trials
- Multimodal Analgesia Effect on Post Surgical Patient (PHASE4)
- Efficacy of Ketamine for Improvement in Postoperative Pain Control After Spinal Fusion for Idiopathic Scoliosis (PHASE4)
- Cyclobenzaprine HCl Extended Release 15 mg Versus Placebo in Treatment of Cervical and/or Lower Back Pain Due to Muscle Spasms of Local Origin (PHASE3)
- Analysis of the Effects of the Osteopathic Manipulative Treatment in Carriers of Temporomandibular Disorders (NA)
- Study Comparing A New Drug Containing The Combination Meloxicam And Cyclobenzaprine In The Treatment Of Acute Lumbago (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Flexeril Oral Product CI brief — competitive landscape report
- Flexeril Oral Product updates RSS · CI watch RSS
- University of California, Davis portfolio CI